Cortendo adds two late‐stage assets and announces $33M financing

Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing Cortendo Enters Into Agreements to Acquire Aspireo Pharmaceuticals’ Somatoprim (DG3173) and In-License Antisense Therapeutics’ ATL1103...

And that’s a wrap! Allicense 2015

From licensing to financing to venture trends, deal-making and beyond, Locust Walk Partners has just come back from an incredible 2-days with our biopharma colleagues from across the world. View Article >